生命科学资讯

Biohaven reduces scope of R&D cutbacks as pipeline progresses

MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit

Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug

TMO (NYSE: TMO) Form 144 lists multiple vested restricted-share lots for sale - Stock Titan

Prolium's $50M Series A raise; COUR Pharma touts liver drug follow-up

Theravance ends R&D, lays off 50% of workers after Phase 3 fail

Financings for March 3, 2026

In the clinic for March 3, 2026

Other news to note for March 3, 2026

Regulatory actions for March 3, 2026

PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub - Zacks Investment Research

Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work

Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market

CMS' Chris Klomp on what it will take for AI to succeed in healthcare

J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks

AI musculoskeletal imaging medtechs Medimaps and Radiobotics pen merger deal

Esperion to buy Corstasis and its nasal spray for edema for $75M upfront

10x Genomics, Inc. (TXG) Stock Analysis: A Closer Look at the Healthcare Innovator’s Growth Potential and Analyst Ratings - DirectorsTalk Interviews

Morgan Stanley Lowers Price Target on Agilent Technologies to $160 From $180, Keeps Overweight Rating - marketscreener.com

Champlain Investment Partners LLC Has $114.97 Million Stock Holdings in Agilent Technologies, Inc. $A - MarketBeat